TherapeuticsMD (TXMD)
(Delayed Data from NSDQ)
$1.79 USD
-0.01 (-0.56%)
Updated Jul 25, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TXMD 1.79 -0.01(-0.56%)
Will TXMD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TXMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TXMD
All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy
TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates
TXMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Organogenesis (ORGO) Lags Q3 Earnings and Revenue Estimates
TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates
Other News for TXMD
TXMD Stock Earnings: TherapeuticsMD Reported Results for Q4 2023
Nektar, Verastem among healthcare additions in Russell Microcap; Assertio, Sangamo removed
TherapeuticsMD: Q1 Earnings Snapshot
TherapeuticsMD Announces First Quarter 2024 Financial Results
TXMD Stock Earnings: TherapeuticsMD Reported Results for Q1 2024